Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients
Johnson & Johnson (NYSE: JNJ ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder. The trial successfully met its primary endpoint, demonstrating a statistically significant and rapid reduction in manic symptoms